Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
Metrics to compare | LIPUM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIPUMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −3.9x | −0.5x | |
PEG Ratio | 0.90 | −0.13 | 0.00 | |
Price/Book | −64.2x | 2.2x | 2.6x | |
Price / LTM Sales | - | 590.2x | 3.1x | |
Upside (Analyst Target) | 11.5% | 0.0% | 57.5% | |
Fair Value Upside | Unlock | 29.1% | 8.6% | Unlock |